Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00066196. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are: * To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. * To determine the safety of MEDI-522 ± DTIC in this patient population.
Study identification
- NCT ID
- NCT00066196
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2003 (Type not available)
- Primary completion
- Apr 2007 (Estimated)
- Completion
- Jun 2007 (Actual)
- Last update posted
- Jan 15, 2008
2003 – 2007
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Saint Francis Memorial Hospital | San Francisco | California | 94109 | — |
| Cancer Institute Medical Group | Santa Monica | California | 90404 | — |
| Medical Group of North County | Vista | California | 92083 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60069 | — |
| Indiana Oncology Hematology Consultants | Indianapolis | Indiana | 46202 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| Johns Hopkins University - SKCC at Johns Hopkins | Lutherville | Maryland | 21093 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Kansas City Oncology & Hematology Group | Kansas City | Missouri | 64131 | — |
| The Melanoma Center of St. Louis | St Louis | Missouri | 63131 | — |
| HemOnc Care, P.C. | Brooklyn | New York | 11235 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| UNC-Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Blumenthal Cancer Center | Charlotte | North Carolina | 28203 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Discovery Alliance | Houston | Texas | 77030 | — |
| The University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00066196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2008 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.